Berlin, 13353, Germany
NCT Number: NCT02957396
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects
Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a novel liquid formulation for the treatment of children in comparison to the adult tablet formulation.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–45 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy male subjects
- Age: 18 to 45 years (inclusive)
- Body mass index (BMI) : ≥ 18 and ≤ 29.9 kg/m²
- Race: White
Exclusion criteria
- Subjects with conspicuous findings in medical history and pre-study examination in the opinion of the investigator
- A history of relevant diseases of vital organs, of the central nervous system or other organs
- Known renal or liver insufficiency
- Subjects with diagnosed malignancy, psychiatric disorders, or thyroid disorders (evaluated by medical history, physical examination, clinical symptoms, and assessment of thyroid stimulating hormone at screening)
- Medical disorder that would impair the subject's ability to complete the study in the opinion of the investigator
- Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
- Relevant diseases within the last 4 weeks prior to the first study drug administration
- Smoking more than 10 cigarettes daily and/ or inability to refrain from smoking on the profile days until 8 h after administration
- Vegetarian or special diets preventing the subjects from eating the standard meals during the study, especially the high-fat high-calorie American breakfast or reluctance to ingest it
Treatment and study plan
Finerenone (BAY94-8862): 20 mg intact tablet
Drug20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet
Drug20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
Finerenone (BAY94-8862): 20 mg suspension
Drug20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
Primary outcomes
-
Finerenone area under the plasma concentration vs. time curve (AUC)
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5. 3, 4, 6, 8, 12, 15 and 24 hours
-
Finerenone maximum plasma concentration (Cmax)
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5. 3, 4, 6, 8, 12, 15 and 24 hours
-
Appearance of oro-dispersible tablets assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
-
Taste of oro-dispersible tablets assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
-
Texture of oro-dispersible tablets assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
-
Smell of oro-dispersible tablets assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
-
Overall impression of oro-dispersible tablets assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
-
Whether oro-dispersible tablets are palatable and swallowable assessed by questionnaire
Time frame: Up to 5 minutes after drug administration
Secondary outcomes
-
Number of patients with adverse events as a measure of safety and tolerability
Time frame: Up to 4 weeks
Sponsors and collaborators
Lead sponsor
Bayer
Industry
Registry information
Official study title
Relative Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of a Single Oral Dose of Finerenone 20 mg as Suspension (Pediatric Formulation), Intact Tablet and Crushed Tablet (Adult Formulation) in the Fasting Condition, and to Investigate the Effect of a High Fat, High Calorie Meal on the Suspension in Healthy Male Subjects in a Randomized, Open-label, Four-fold Crossover Design.
Important dates
- Study start
- 2016
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Nov 7, 2016
- Registry last updated
- Apr 24, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers
NCT07560150
Insulin Aspart, Pharmacodynamics
Chula Vista, California, United States
View Trial DetailsPhase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
NCT05142592
Pharmacokinetics, Safety Issues
Portland, Oregon, United States
View Trial DetailsScavenging of Reactive Carbonyl Species by Apple Polyphenols in Human
NCT03911050
Human Health, Pharmacokinetics
Kannapolis, North Carolina, United States
View Trial DetailsPharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery
NCT05328778
Pharmacokinetics
Guangzhou, Guangdong, China
View Trial Details